Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee

Key Concepts

• Amgen's Obesity Drug (MariTide): A new monthly obesity shot being developed by Amgen, with potential data releases expected before year-end.
• Eli Lilly (Lilly): A major player in the obesity drug market, currently with significant market share and a strong pipeline.
• Novo Nordisk (Novo): Another key competitor in the obesity drug space, with multiple drugs on the market and in advanced clinical studies.
• Obesity Drug Market: A rapidly growing market projected to reach $20 billion in the US this year and $150 billion by 2030.
• Incretins and Amylins: Drug classes that are central to the transformative potential of obesity treatments, impacting chronic conditions.
• Morbidity, Mortality, and Cost: The key areas where obesity drugs are showing significant impact beyond weight loss.
• Valuation: The market's assessment of a company's worth, particularly in relation to its earnings and future prospects.
• ICER (Institute for Clinical and Economic Research): An organization that analyzes drug costs and value, with recent findings on the cost-effectiveness of obesity drugs.
• Zeppound and Wegovy: Specific obesity drugs mentioned, with Zeppound noted as potentially better than Wegovy at a lower price.

Amgen's MariTide and Potential Market Impact

• Data Readouts: Attention is shifting to new competitors like Amgen, which is expected to release new data on its monthly obesity shot, MariTide, before the end of the year.
• Key Data Focus: The critical aspect of the upcoming Phase Two study data for MariTide will be the incidence of nausea and vomiting. The efficacy of the drug is less of a concern than its side effect profile.
• Market Share Concerns: A significant concern for MariTide is its projected FDA approval timeline of 2028 or 2029. By that time, Eli Lilly is expected to have three obesity drugs on the market and four in advanced clinical studies, while Novo Nordisk will have three drugs on the market and at least one significant drug in advanced clinical study.
• Competitive Landscape: Even if MariTide proves to be a promising once-a-month drug (an advancement over current weekly treatments) or potentially a once-every-three-months option, its late market entry could severely limit its market share potential.
• Short-Term vs. Long-Term Impact: While favorable MariTide data could lead to a short-term hit on Lilly's shares as investors take profits, the longer-term outlook suggests Lilly could remain in a strong position. Novo Nordisk is identified as a potential "value play."

Eli Lilly's Valuation and Future Prospects

• Significant Growth: Lilly's stock has already seen substantial gains, with a price target of $1,100 established three years ago having been met.
• Valuation Concerns: Lilly is trading at a premium, approximately 35 times next year's earnings, which is significantly higher than competitors like Merck and Bristol Myers Squibb (trading at 11-12 times earnings).
• Premium Justification: While Lilly's strong pipeline and market position justify a premium, the question arises at what point valuation becomes a concern.
• Analyst's Estimate: The analyst's estimate for Lilly's earnings next year is $35 per share, placing the stock at about 31 times that estimate.
• Profit-Taking Potential: At its current valuation, favorable MariTide data could prompt investors to take profits in Lilly, given its outstanding performance.

Broader Pharmaceutical Market and Transformative Drug Class

• Pharmaceutical Research Renaissance: The market is experiencing a "pharmaceutical research renaissance" at a time when valuations were previously low, leading to a necessary resolution of valuation disparities.
• Merck and Bristol Myers Squibb: These companies have strong pipelines in other areas, with Merck having 30 drugs in Phase Three and a significant oncology pipeline. However, they are not expected to be major players in the obesity drug category.
• Obesity Drug Market Growth: The US obesity drug market is projected to grow from $20 billion this year to $150 billion by 2030.
• Transformative Drug Class: The analyst describes obesity drugs (incretins and amylins) as the "most transformative drug class" of his career.
• Beyond Weight Loss: The significance of these drugs lies not just in obesity treatment but in their ability to prevent morbidity, mortality, and costs associated with seven of the most common chronic conditions in the US.
• ICER Findings: The Institute for Clinical and Economic Research (ICER) recently held a symposium where they stated that Zeppound, at a lower price and in conjunction with lifestyle management, was not only better than lifestyle management alone but also resulted in cost savings. This highlights the economic benefits beyond improved quality of life.

Conclusion

The discussion highlights the dynamic and rapidly evolving landscape of the obesity drug market. While Amgen's upcoming data on MariTide could create short-term volatility for Eli Lilly, Lilly's established market position and strong pipeline suggest continued long-term strength. Novo Nordisk is positioned as a potential value play. The broader significance of incretin and amylin-based obesity drugs extends beyond weight loss, offering substantial benefits in managing chronic conditions and potentially generating significant cost savings, as indicated by recent ICER findings. The market is currently valuing Lilly at a premium, and while justified by its performance, it raises questions about future growth potential.